About Stoke Therapeutics Inc.

Stoke Therapeutics Inc., founded in 2014, is pioneering a novel approach to treating genetic diseases by developing medicines that increase production of functional proteins from a patient's existing genes. The company's TANGO platform targets genetic diseases caused by insufficient protein production. STOK stock price reflects investor interest in the company's innovative scientific approach and clinical pipeline addressing severe genetic disorders.

Led by CEO Edward Kaye, MD, Stoke Therapeutics has assembled a team of experienced drug developers and geneticists to advance its RNA-based platform. The management team combines deep scientific expertise with proven clinical development capabilities. Leadership's strategic focus on advancing the TANGO platform through clinical trials while building additional programs has been important for creating value and influencing STOK stock price potential.

Stoke operates by developing antisense oligonucleotides that modulate RNA splicing to increase functional protein production from genes with mutations causing genetic diseases. The company's lead programs target Dravet syndrome and other severe genetic disorders affecting the central nervous system. With novel approach addressing root causes of genetic diseases, multiple clinical programs providing catalyst opportunities, and significant unmet medical needs in rare genetic disorders, STOK offers investors exposure to innovative genetic medicine with potential for transformative treatments, though early-stage development carries inherent risks and requires successful clinical validation.